AVEO Pharmaceuticals, Inc. (AVEO)

[stockgringo]

Why $AVEO might be one of the best Biotech longs to own before 2016- DD

Now might be the time to look at $AVEO biotech- Great management team has positioned the company very well to have a block buster year in 2016. There are a number of catalyst that should come out by years end.
- Looking for the announcement of Tivozanib partnership in EU
- MAA Filing
- $ Initiation of Phase 3 third line RCC study
- Selection of prototype for NRP-1 companion diagnostic for CRC study
COOP group Feedback on CRC study
$- AV 203 Partnership announcement
In 2016 looking for milestone payments from Novartis, Ophothotech and Pharmstandard that should be in the 40-300 mil range.. The current price @ 1.23 and with 26.8 M currently in cash as of 2Q15 makes fits the criteria for finding the stocks with the most potential going forward. For instance Assuming even if the revs in 2016 are 50 mil, with only 55.7 million shares in the outstanding, this stock price would trade over 10 bucks assuming a very conservative PE of 10. We all know Biotechs can trade at a 100 PE. This is why I ranked AVEO as my second favorite Biotech to own before 2016